173 related articles for article (PubMed ID: 24299320)
1. Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer.
Imai H; Takahashi T; Mori K; Ono A; Akamatsu H; Shukuya T; Taira T; Kenmotsu H; Naito T; Murakami H; Endo M; Nakajima T; Yamamoto N
Neoplasma; 2014; 61(2):233-40. PubMed ID: 24299320
[TBL] [Abstract][Full Text] [Related]
2. Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy.
Imai H; Mori K; Ono A; Akamatsu H; Taira T; Kenmotsu H; Naito T; Kaira K; Murakami H; Endo M; Nakajima T; Takahashi T
Med Oncol; 2014 Aug; 31(8):88. PubMed ID: 24961467
[TBL] [Abstract][Full Text] [Related]
3. Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy.
Kotake M; Miura Y; Imai H; Mori K; Sakurai R; Kaira K; Tomizawa Y; Minato K; Saito R; Hisada T
Chemotherapy; 2017; 62(4):205-213. PubMed ID: 28380484
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.
Kim YH; Hirabayashi M; Togashi Y; Hirano K; Tomii K; Masago K; Kaneda T; Yoshimatsu H; Otsuka K; Mio T; Tomioka H; Suzuki Y; Mishima M
Cancer Chemother Pharmacol; 2012 Aug; 70(2):271-6. PubMed ID: 22752216
[TBL] [Abstract][Full Text] [Related]
5. Postprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy.
Hayashi H; Okamoto I; Taguri M; Morita S; Nakagawa K
Clin Lung Cancer; 2013 May; 14(3):261-6. PubMed ID: 23107465
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of postprogression survival for overall survival in elderly patients (aged 75 years or older) with advanced nonsmall cell lung cancer.
Yoshino R; Imai H; Mori K; Tomizawa Y; Takei K; Tomizawa M; Kaira K; Yoshii A; Watanabe S; Saito R; Yamada M
J Cancer Res Ther; 2015; 11(3):606-11. PubMed ID: 26458589
[TBL] [Abstract][Full Text] [Related]
7. The effect of post-progression survival on overall survival among patients with sensitive relapse of small cell lung cancer.
Miura Y; Imai H; Sakurai R; Kaira K; Sunaga N; Minato K; Saito R; Hisada T
Med Oncol; 2018 Mar; 35(4):45. PubMed ID: 29508094
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of post-progression survival on overall survival in elderly patients with extensive disease small-cell lung cancer.
Imai H; Mori K; Watase N; Kazama T; Fujimoto S; Kaira K; Yamada M; Minato K
Thorac Cancer; 2016 Nov; 7(6):655-662. PubMed ID: 27755823
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.
Schuette WH; Gröschel A; Sebastian M; Andreas S; Müller T; Schneller F; Guetz S; Eschbach C; Bohnet S; Leschinger MI; Reck M
Clin Lung Cancer; 2013 May; 14(3):215-23. PubMed ID: 23332288
[TBL] [Abstract][Full Text] [Related]
10. Thrombocytosis and immunohistochemical expression of connexin 43 at diagnosis predict survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.
Du G; Yang Y; Zhang Y; Sun T; Liu W; Wang Y; Li J; Zhang H
Cancer Chemother Pharmacol; 2013 Apr; 71(4):893-904. PubMed ID: 23355038
[TBL] [Abstract][Full Text] [Related]
11. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
Paz-Ares LG; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
J Clin Oncol; 2013 Aug; 31(23):2895-902. PubMed ID: 23835707
[TBL] [Abstract][Full Text] [Related]
12. Third-line therapy in advanced non-small cell lung cancer.
Ying Geng Z; Chang Jiao S; Cui Liu S; Li Y; Feng Liu Z; Qing Zhang G; Jie Wang L; Qu F
J BUON; 2013; 18(4):899-907. PubMed ID: 24344015
[TBL] [Abstract][Full Text] [Related]
13. Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer.
Mir O; Boudou-Rouquette P; Giroux J; Chapron J; Alexandre J; Gibault L; Ropert S; Coriat R; Durand JP; Burgel PR; Dusser D; Goldwasser F
Lung Cancer; 2012 Jul; 77(1):104-9. PubMed ID: 22364783
[TBL] [Abstract][Full Text] [Related]
14. Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial.
Ardizzoni A; Tiseo M; Boni L; Vincent AD; Passalacqua R; Buti S; Amoroso D; Camerini A; Labianca R; Genestreti G; Boni C; Ciuffreda L; Di Costanzo F; de Marinis F; Crinò L; Santo A; Pazzola A; Barbieri F; Zilembo N; Colantonio I; Tibaldi C; Mattioli R; Cafferata MA; Camisa R; Smit EF
J Clin Oncol; 2012 Dec; 30(36):4501-7. PubMed ID: 23109689
[TBL] [Abstract][Full Text] [Related]
15. An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer.
Nuijten MJ; Aultman R; Carpeño Jde C; Vergnenègre A; Chouaid C; Walzer S; Siebert U
Curr Med Res Opin; 2011 Nov; 27(11):2193-201. PubMed ID: 21970659
[TBL] [Abstract][Full Text] [Related]
16. Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.
Zhang YF; Chen ZW; Lu S
Chin Med J (Engl); 2009 Oct; 122(20):2472-6. PubMed ID: 20079162
[TBL] [Abstract][Full Text] [Related]
17. A meta-analysis of paclitaxel-based chemotherapies administered once every week compared with once every 3 weeks first-line treatment of advanced non-small-cell lung cancer.
Gao G; Chu H; Zhao L; Gui T; Xu Q; Shi J
Lung Cancer; 2012 Jun; 76(3):380-6. PubMed ID: 22226626
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
Spigel DR; Burris HA; Greco FA; Shipley DL; Friedman EK; Waterhouse DM; Whorf RC; Mitchell RB; Daniel DB; Zangmeister J; Bass JD; Hainsworth JD
J Clin Oncol; 2011 Jun; 29(18):2582-9. PubMed ID: 21576636
[TBL] [Abstract][Full Text] [Related]
19. Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer.
Imai H; Mori K; Wakuda K; Ono A; Akamatsu H; Shukuya T; Taira T; Kenmotsu H; Naito T; Kaira K; Murakami H; Endo M; Nakajima T; Yamamoto N; Takahashi T
Ann Thorac Med; 2015; 10(1):61-6. PubMed ID: 25593610
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of post-progression survival on overall survival in patients receiving nivolumab monotherapy as a second-line treatment for advanced non-small cell lung cancer.
Imai H; Yamaguchi O; Mori K; Hashimoto K; Akagami T; Shinomiya S; Miura Y; Shiono A; Mouri A; Kaira K; Kobayashi K; Kagamu H
Thorac Cancer; 2021 Apr; 12(8):1171-1179. PubMed ID: 33626218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
